Isis ends RA, continues cardiovascular programs for ISIS-CRPRx
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals will discontinue development of ISIS-CRPRx in the treatment of rheumatoid arthritis (RA) after the antisense drug targeting C-reactive protein (CRP) decreased CRP by as much as 67%, but did not provide a statistically significant improvement in the signs and symptoms of RA compared with placebo in a 51-patient Phase II clinical trial.